The numbers
The BA.3.2 variant of COVID-19, first identified in South Africa in November 2024, has now been detected in 29 U.S. states and Puerto Rico. As of March 12, 2026, it has appeared in nasal swabs from six U.S. travelers, three airplane wastewater samples, 29 patients, and 260 wastewater samples. This alarming spread has prompted health officials to closely monitor its evolution and impact.
BA.3.2 is notable for its significant genetic alterations, featuring approximately 70 to 75 mutations in its spike protein compared to the antigens used in current vaccines. This raises concerns about the variant’s ability to evade immunity, as laboratory studies suggest it may efficiently bypass antibodies generated from previous infections or vaccinations. Researchers emphasize the importance of tracking BA.3.2 to understand its potential to undermine vaccine effectiveness.
During the period from December 1, 2025, to March 12, 2026, the prevalence of BA.3.2 detections among 5,238 sequences was recorded at 0.55%. This figure indicates that while the variant is present, it has not yet dominated the viral landscape. However, it has been reported by at least 23 countries as of February 11, 2026, highlighting its global reach.
In Europe, BA.3.2 has cocirculated with various JN.1 descendant lineages, with prevalence rates ranging from 10% to 40% in several countries, including Denmark, Germany, and the Netherlands. Phylogenetic analyses have also identified two sublineages of BA.3.2: BA.3.2.1 and BA.3.2.2, which may have different implications for public health and vaccine response.
The public health impact of COVID-19 remains significant, with estimates suggesting between 390,000 and 550,000 hospitalizations and 45,000 to 64,000 deaths during the 2024-2025 respiratory virus season. These figures underscore the ongoing threat posed by COVID-19, even as new variants like BA.3.2 emerge.
Wastewater surveillance has proven to be an effective early warning system for detecting BA.3.2. This method allows health authorities to identify the presence of the virus in communities, potentially leading to quicker responses to outbreaks. However, researchers caution that many countries have limited genomic detection and surveillance capacities, which may lead to an underrepresentation of the actual geographic spread of BA.3.2.
As the situation evolves, continued genomic surveillance is crucial to track the evolution of SARS-CoV-2 and assess its potential effects on public health. Details remain unconfirmed regarding the full impact of BA.3.2 on human health outcomes, leaving experts vigilant and concerned about the future trajectory of the pandemic.
